Match tier
Listed
Presence
Current · Arkansas
Last published
2023
Sources
OpenAlex · ORCID
Refreshed
2026-10-06
E
Erming Tian
High Impact
Role not yet determined Is this you? Add your title
Also affiliated: University of Maryland, Baltimore (2003); Hackensack University Medical Center (2003); Harvard University (2003); Medical College of Wisconsin (2003); Norwegian University of Science and Technology (2006–2016); Cornell University (2001); University of Arkansas Medical Center (1999–2023); Universitätsklinikum Erlangen (2003); Fred Hutch Cancer Center (2002); Cancer Research And Biostatistics (2003); Dana-Farber/Harvard Cancer Center (2003); National Cancer Institute (2001); University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (2003)
32 h-index
100 pubs
5,650 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Erming Tian's research focuses on the molecular mechanisms underlying multiple myeloma, a cancer of plasma cells. His work has investigated gene expression profiles in multiple myeloma and related conditions, aiming to identify molecular markers for diagnosis and therapy. This includes studies on the dysregulation of genes, such as Cyclin D3, through chromosomal translocations in myeloma.
Tian has also explored specific signaling pathways and cellular processes involved in myeloma progression. His research has examined the role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions and the control of autophagic cell death by Caspase-10. Additionally, his work has addressed mechanisms of relapse in myeloma, including clonal selection and the involvement of tumor suppressor genes. His scholarship metrics include an h-index of 32, with over 5,580 citations across more than 100 publications, designating him as a highly cited researcher.
Metrics
- h-index: 32
- Publications: 100
- Citations: 5,650
Selected Publications
-
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma (2023)
-
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma (2021)
-
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021)
-
Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience (2021)
-
Innate Biomineralization (2020)
-
Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome (2019)
-
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome (2019)
-
Identification of novel breakpoints for locus- and region-specific translocations in 293 cells by molecular cytogenetics before and after irradiation (2019)
-
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma (2019)
-
Microhomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma (2019)
-
An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome (2018)
-
Fluorescence In Situ Hybridization (FISH) in Multiple Myeloma (2018)
-
MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern (2017)
-
Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma (2017)
-
Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status (2017)
Collaboration Network
Top Collaborators
Bart Barlogie
University of Arkansas for Medical Sciences
41 shared publications
In database
- The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
- Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains anIGH/MMSET fusion transcript
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
Showing 5 of 41 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
28 shared publications
In database
- The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
- Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
- Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma
- A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains anIGH/MMSET fusion transcript
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
Showing 5 of 28 shared publications
Frits van Rhee
Winthrop Rockefeller Foundation
25 shared publications
In database
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
Showing 5 of 25 shared publications
Joshua Epstein
University of Arkansas for Medical Sciences (US)
24 shared publications
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
- High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification
Showing 5 of 24 shared publications
Jeffrey R. Sawyer
University of Arkansas for Medical Sciences (US)
24 shared publications
- Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma
- High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
- Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
- Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q
- Evi27 encodes a novel membrane protein with homology to the IL17 receptor
Showing 5 of 24 shared publications
Maurizio Zangari
Winthrop Rockefeller Foundation
20 shared publications
In database
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
Showing 5 of 20 shared publications
Christoph Johann Heuck
University of Arkansas for Medical Sciences (US)
17 shared publications
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- Prediction of cytogenetic abnormalities with gene expression profiles
Showing 5 of 17 shared publications
Gareth John Morgan
University of Arkansas for Medical Sciences (US)
16 shared publications
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
Showing 5 of 16 shared publications
Owen Stephens
University of Arkansas for Medical Sciences (US)
13 shared publications
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
- An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification
- Prediction of cytogenetic abnormalities with gene expression profiles
- Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma
Showing 5 of 13 shared publications
Carolina Schinke
Winthrop Rockefeller Foundation
13 shared publications
In database
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
Showing 5 of 13 shared publications
Faith E. Davies
University of Arkansas for Medical Sciences (US)
12 shared publications
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
Showing 5 of 12 shared publications
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
12 shared publications
In database
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 12 shared publications
Janet L. Lukacs
University of Arkansas for Medical Sciences
10 shared publications
In database
- Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
Showing 5 of 10 shared publications
Gael Sammartino
University of Arkansas for Medical Sciences
10 shared publications
In database
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
- Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC
Showing 5 of 10 shared publications
Brian A. Walker
University of Arkansas for Medical Sciences (US)
10 shared publications
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
- An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
- An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome
Showing 5 of 10 shared publications
Similar Researchers
Based on overlapping research topics
Fenghuang Zhan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Gene expression and cancer classification
Christophe Bobda
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders
Molecular Biology Techniques and Applications
S. G. Lamb
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders
Molecular Biology Techniques and Applications
John D. Shaughnessy
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Gene expression and cancer classification
R. D. Henderson
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders
Molecular Biology Techniques and Applications
Guido J. K. Tricot
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders